Trial Profile
Phase 1 study of neoadjuvant chemotherapy with capecitabine/bevacizumab for locally advanced lower rectal cancer.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 12 May 2016
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Capecitabine (Primary)
- Indications Rectal cancer
- Focus Adverse reactions
- 25 Mar 2013 Planned end date changed from 1 Mar 2013 to 31 Jul 2013 as reported by University Hospital Medical Information Network - Japan.
- 24 Mar 2011 New trial record